ERDERA to attend the World Orphan Drug Congress Europe 2025

blank

ERDERA is pleased to announce its participation in the upcomingWorld Orphan Drug Congress Europe 2025, taking place from27 to 29 October at theRAI Congress Centre in Amsterdam. Make sure to come and visit us at our booth 10.512!

Orphan drugs are medicines developed specifically to diagnose, prevent, or treat rare diseases—conditions that individually affect only a small number of patients, but collectively impact over 30 million people in Europe. Because of the limited market potential, these therapies often require dedicated incentives, regulatory support, and international collaboration to come to fruition.

Often described as the largest and most established global event fororphan drugs and rare diseases, the World Orphan Drug Congresswill once again serve as a key platform for innovation, collaboration and strategic dialogue across the entire orphan drug lifecycle, and ERDERA is happy to be present in this conversation.

The World Orphan Drug Congress Europe brings togetherover 2 000 attendees,250+ expert speakers, andmore than 130 exhibitors, offering unparalleled networking and learning opportunities. From regulatory affairs and policy to cutting-edgegene therapies, global pricing, patient engagement and access strategies, the event covers a broad and dynamic range of topics shaping the future of rare disease care and orphan drug development.

Attendees include senior leaders from pharmaceutical and biotech industries, researchers, patient advocates, policymakers, healthcare professionals, and representatives from regulatory bodies. The event is widely regarded as a vital space to share insights, build partnerships, and advance the field of rare diseases.

ERDERA’s presence at the congress reaffirms its commitment to fostering cross-sectoral collaboration, sharing expertise, and contributing to policy discussions that impact people living with rare diseases across Europe. Several of ERDERA’s partners will bespeakers at the congress, highlighting the project’s ongoing work in strengthening the evidence base for rare disease care. Among them isDaria Julkowska, ERDERA’s Scientific Coordinator, who will be contributing her expertise and strategic perspective on the European rare disease landscape.

Key dates

  • 27 October 2025 – Pre-Congress Workshops
  • 28–29 October 2025 – Main Congress Days
  • RAI Congress Centre, Amsterdam

Learn more about the event and apply for complimentary tickets:

News & Updates

You might also be interested in

30 million people in Europe live with a rare disease. Yet most still lack a diagnosis or treatment. So what is ERDERA doing about it?
ERDERA will launch its Clinical Trial Call 2026 (ECTC) on 1 July 2026, supporting multinational, GCP‑compliant early‑phase interventional clinical trials in rare diseases.
Pre-announcement describing scope, eligibility and indicative timeline for the ERDERA Clinical Trial Call 2026, expected to open on 1 July 2026.
Budget example showing low and high cost ranges for a Phase 1 rare disease clinical trial with twenty subjects.